UCLA Health researchers say study findings uncover Huntington's disease mechanisms and pave new ways to develop treatments.

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder <l ...

Prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources ...

REM sleep behavior disorder is characterized by acting out dreams, which may include shouting, kicking and punching during sleep.

After Hiding My Undiagnosed Neurological Condition for Decades, I Finally Found Answers A personal quest and progress in ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

AMT-130. The company's lead clinical program is AMT-130, a micro RNA (miRNA) AAV5 gene therapy for the treatment of Huntington's disease, a rare genetic disorder that causes nerve cells in the ...

From its base at the Milner Therapeutics Institute, TRIMTECH is developing a pipeline of potent, CNS (central nervous system) ...

What initially seems like purely psychological trouble may indeed have roots in physical conditions that, once identified, ...

Living in Ireland for a decade, the compulsive liar - now in prison for social welfare fraud - deceived almost everyone she ...

ALZcure is pioneering blockchain-powered funding for Alzheimer's research through Decentralized Science (DeSci). Built on ...